vs
Side-by-side financial comparison of Adient plc (ADNT) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Adient plc is the larger business by last-quarter revenue ($3.6B vs $2.8B, roughly 1.3× Bausch Health Companies Inc.). Adient plc runs the higher net margin — -0.6% vs -3.7%, a 3.1% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 4.3%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $15.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -1.4%).
Adient plc is an American, Irish-domiciled company that operates as the largest manufacturer of automotive seating for customers worldwide and is based in Plymouth, Michigan, United States.
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
ADNT vs BHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $2.8B |
| Net Profit | $-22.0M | $-103.0M |
| Gross Margin | 6.0% | — |
| Operating Margin | 1.1% | 17.0% |
| Net Margin | -0.6% | -3.7% |
| Revenue YoY | 4.3% | 9.3% |
| Net Profit YoY | — | -205.1% |
| EPS (diluted) | $-0.28 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.6B | $2.8B | ||
| Q3 25 | $3.7B | $2.7B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $3.6B | $2.3B | ||
| Q4 24 | $3.5B | $2.6B | ||
| Q3 24 | $3.6B | $2.5B | ||
| Q2 24 | $3.7B | $2.4B | ||
| Q1 24 | $3.8B | $2.2B |
| Q4 25 | $-22.0M | $-103.0M | ||
| Q3 25 | $18.0M | $179.0M | ||
| Q2 25 | $36.0M | $148.0M | ||
| Q1 25 | $-335.0M | $-58.0M | ||
| Q4 24 | $0 | $98.0M | ||
| Q3 24 | $79.0M | $-85.0M | ||
| Q2 24 | $-11.0M | $10.0M | ||
| Q1 24 | $-70.0M | $-64.0M |
| Q4 25 | 6.0% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 6.2% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 6.1% | — |
| Q4 25 | 1.1% | 17.0% | ||
| Q3 25 | 1.7% | 23.1% | ||
| Q2 25 | 1.8% | 17.5% | ||
| Q1 25 | -7.3% | 12.2% | ||
| Q4 24 | 1.3% | 21.8% | ||
| Q3 24 | 1.8% | 12.7% | ||
| Q2 24 | 1.2% | 16.2% | ||
| Q1 24 | -1.1% | 13.1% |
| Q4 25 | -0.6% | -3.7% | ||
| Q3 25 | 0.5% | 6.7% | ||
| Q2 25 | 1.0% | 5.8% | ||
| Q1 25 | -9.3% | -2.6% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 2.2% | -3.4% | ||
| Q2 24 | -0.3% | 0.4% | ||
| Q1 24 | -1.9% | -3.0% |
| Q4 25 | $-0.28 | $-0.30 | ||
| Q3 25 | $0.17 | $0.48 | ||
| Q2 25 | $0.43 | $0.40 | ||
| Q1 25 | $-3.99 | $-0.16 | ||
| Q4 24 | $0.00 | $0.24 | ||
| Q3 24 | $0.88 | $-0.23 | ||
| Q2 24 | $-0.12 | $0.03 | ||
| Q1 24 | $-0.77 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.3B |
| Total DebtLower is stronger | $2.4B | $20.8B |
| Stockholders' EquityBook value | $1.7B | $-554.0M |
| Total Assets | $8.8B | $26.4B |
| Debt / EquityLower = less leverage | 1.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $719.0M | ||
| Q2 24 | — | $595.0M | ||
| Q1 24 | — | $733.0M |
| Q4 25 | $2.4B | $20.8B | ||
| Q3 25 | $2.4B | $21.0B | ||
| Q2 25 | $2.4B | $21.7B | ||
| Q1 25 | $2.4B | $21.5B | ||
| Q4 24 | $2.4B | $21.6B | ||
| Q3 24 | $2.4B | $21.5B | ||
| Q2 24 | $2.4B | $21.7B | ||
| Q1 24 | $2.4B | $22.1B |
| Q4 25 | $1.7B | $-554.0M | ||
| Q3 25 | $1.8B | $-565.0M | ||
| Q2 25 | $1.8B | $-764.0M | ||
| Q1 25 | $1.7B | $-1.2B | ||
| Q4 24 | $1.9B | $-1.3B | ||
| Q3 24 | $2.1B | $-1.2B | ||
| Q2 24 | $1.9B | $-1.2B | ||
| Q1 24 | $2.1B | $-1.1B |
| Q4 25 | $8.8B | $26.4B | ||
| Q3 25 | $9.0B | $26.8B | ||
| Q2 25 | $8.8B | $27.3B | ||
| Q1 25 | $8.6B | $26.4B | ||
| Q4 24 | $8.5B | $26.5B | ||
| Q3 24 | $9.4B | $26.5B | ||
| Q2 24 | $9.1B | $26.5B | ||
| Q1 24 | $9.3B | $26.9B |
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 1.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.0M | $495.0M |
| Free Cash FlowOCF − Capex | $15.0M | $403.0M |
| FCF MarginFCF / Revenue | 0.4% | 14.4% |
| Capex IntensityCapex / Revenue | 1.8% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $174.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.0M | $495.0M | ||
| Q3 25 | $213.0M | $405.0M | ||
| Q2 25 | $172.0M | $289.0M | ||
| Q1 25 | $-45.0M | $211.0M | ||
| Q4 24 | $109.0M | $601.0M | ||
| Q3 24 | $263.0M | $405.0M | ||
| Q2 24 | $158.0M | $380.0M | ||
| Q1 24 | $81.0M | $211.0M |
| Q4 25 | $15.0M | $403.0M | ||
| Q3 25 | $134.0M | $314.0M | ||
| Q2 25 | $115.0M | $190.0M | ||
| Q1 25 | $-90.0M | $96.0M | ||
| Q4 24 | $45.0M | $495.0M | ||
| Q3 24 | $191.0M | $334.0M | ||
| Q2 24 | $88.0M | $302.0M | ||
| Q1 24 | $12.0M | $129.0M |
| Q4 25 | 0.4% | 14.4% | ||
| Q3 25 | 3.6% | 11.7% | ||
| Q2 25 | 3.1% | 7.5% | ||
| Q1 25 | -2.5% | 4.2% | ||
| Q4 24 | 1.3% | 19.3% | ||
| Q3 24 | 5.4% | 13.3% | ||
| Q2 24 | 2.4% | 12.6% | ||
| Q1 24 | 0.3% | 6.0% |
| Q4 25 | 1.8% | 3.3% | ||
| Q3 25 | 2.1% | 3.4% | ||
| Q2 25 | 1.5% | 3.9% | ||
| Q1 25 | 1.2% | 5.1% | ||
| Q4 24 | 1.8% | 4.1% | ||
| Q3 24 | 2.0% | 2.8% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 1.8% | 3.8% |
| Q4 25 | — | — | ||
| Q3 25 | 11.83× | 2.26× | ||
| Q2 25 | 4.78× | 1.95× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.13× | ||
| Q3 24 | 3.33× | — | ||
| Q2 24 | — | 38.00× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADNT
Segment breakdown not available.
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
